

# MESCO PHARMACEUTICALS LIMITED

Corporate Identity No. L24111UR1986PLC015895

Regd. Office: Upper Kesalton, Tallital, Nainital-263 001, Uttarakhand,

W: [www.mescopharma.com](http://www.mescopharma.com) E-mail: [nsparameswaran@mescosteel.com](mailto:nsparameswaran@mescosteel.com), Tel: 9871862796

MPL/33/QTR-1/2020-2021

03<sup>rd</sup> September, 2020

The Listing Department  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai-400001

**Scrip ID: MESPHAR-B**

**Scrip Code: 500274**

**Sub: Un-Audited Financial Results for the Quarter ended 30<sup>th</sup> June, 2020**

Dear Sir,

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Un-Audited Financial Results for the Quarter ended 30<sup>th</sup> June, 2020.

M/s. Sangram Paul & Co., Chartered Accountants, Statutory Auditors of the Company has issued the Limited Review Report

The Board meeting commenced at 02:30 and concluded at 03:30 pm.

A Copy of the said results together with Limited Review Report is enclosed herewith. These results are also being made available on the website of the Company at [www.mescopharma.com](http://www.mescopharma.com)

This is for your information and records.

Thanking You,

Yours Faithfully,

For **Mesco Pharmaceuticals Limited**

  
**N S Parameswaran**

**Company Secretary cum Compliance Officer**

# Sangram Paul & Co.

**S.K. Paul. F.C.A**  
Chartered Accountant

**Chartered Accountants**  
Plot No.-754/15, Jayadev Vihar, Bhubaneswar-751 013  
Phone : 0674-2360863, Mob. : 9337116878

## **Review Report to MESCO PHARMACEUTICALS LIMITED**


We have reviewed the accompanying statement of Standalone Unaudited financial results of **MESCO PHARMACEUTICALS LIMITED** for the quarter ended June 30, 2020 being submitted by the company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, read with SEBI circular CIR/CFD/FAC/62/2016 dated July 5, 2016.

This statement is the responsibility of the Company's Management and approved by the Board of Directors has been prepared in accordance with Indian Accounting Standard ("IND-AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles general accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No: CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Sangram Paul & Co.**  
**Chartered Accountants**  
**Firm Registration No. 308001E**



**S.K. Paul**  
**Proprietor**  
**M. No.: - 013015**  
**UDIN: 20013015AAAAA03917**

**Date: 03<sup>rd</sup> September, 2020**  
**Place: New Delhi**

## MESCO PHARMACEUTICALS LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2020						
(Figures in Rs.)						
Part - I						
	Particulars	Quarter ended			Year ended	
		30.06.2020 (Unaudited)	31.03.2020 (Unaudited)	30.06.2019 (Unaudited)	31.03.2020 (Audited)	31.03.2019 (Audited)
I	Revenue From Operations	-	-	-	-	-
II	Other Income	-	-	-	-	-
III	<b>Total Income (I + II)</b>	-	-	-	-	-
IV	<b>EXPENSES</b>					
	Cost of materials consumed	-	-	-	-	-
	Purchase of Stock-in Trade	-	-	-	-	-
	Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	-	-	-	-	-
	Employee benefits expense	-	-	-	-	-
	Finance Cost	-	-	-	-	-
	Depreciation and amortisation expense	-	-	-	-	-
	Other Expenses	6,000	6,295	854,355	983,321	4,098,033
	<b>Total Expenses (IV)</b>	<b>6,000</b>	<b>6,295</b>	<b>854,355</b>	<b>983,321</b>	<b>4,098,033</b>
V	Profit/(loss) before exceptional items and tax (I-IV)	(6,000)	(6,295)	(854,355)	(983,321)	(4,098,033)
VI	Exceptional items	-	-	-	-	-
VII	<b>Profit/(Loss) Before Tax (V-VI)</b>	<b>(6,000)</b>	<b>(6,295)</b>	<b>(854,355)</b>	<b>(983,321)</b>	<b>(4,098,033)</b>
VIII	Tax Expense:					
	(1) Current Tax	-	-	-	-	-
	(2) Deferred Tax	-	-	-	-	-
IX	<b>Profit/(Loss) for the period from Continuing Operations (VII-VIII)</b>	<b>(6,000)</b>	<b>(6,295)</b>	<b>(854,355)</b>	<b>(983,321)</b>	<b>(4,098,033)</b>
X	Profit/(Loss) from discontinued Operations	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-
XII	<b>Profit/(loss) from Discontinued operations (after tax) (X+XI)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XIII	<b>Profit/(Loss) for the period (IX+XII)</b>	<b>(6,000)</b>	<b>(6,295)</b>	<b>(854,355)</b>	<b>(983,321)</b>	<b>(4,098,033)</b>
XIV	Other Comprehensive Income	-	-	-	-	-
XV	<b>Total Comprehensive Income for the period (XIII+XIV) (Comprising</b>	<b>(6,000)</b>	<b>(6,295)</b>	<b>(854,355)</b>	<b>(983,321)</b>	<b>(4,098,033)</b>
XVI	<b>Earnings/(Loss) Per Equity Share (for continuing operation):</b>					
	Basic and Diluted (face value of Rs. 10 each)	(0.00)	(0.00)	(0.04)	(0.05)	(0.20)
XVII	<b>Earnings/(Loss) Per Equity Share (for discontinued operation):</b>					
	Basic and Diluted (face value of Rs. 10 each)	-	-	-	-	-
XVIII	<b>Earnings/(Loss) Per Equity Share (for discontinued and Continuing</b>					
	Basic and Diluted (face value of Rs. 10 each)	(0.00)	(0.00)	(0.04)	(0.05)	(0.20)

## Notes

- 1) The Company has adopted Indian Accounting Standards (IND AS) prescribed under the Companies Act, 2013 read with relevant rules thereunder, with effect from April 1, 2017 and accordingly these financial results have been prepared in accordance with the measurement and recognition principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with relevant rules made thereunder
- 2) The Statutory Auditors of the Company have carried out Limited Review of the above Results.
- 3) The above audited financial results for the quarter and year ended on June 30, 2020 have been reviewed by the Audit Committee and have been approved by the Board of Directors in its meeting held on 03.09.2020
- 4) Previous year period figures have been rearranged and regrouped wherever necessary to make them comparable with current period figures.
- 5) There were no manufacturing activities in the Company during the period under consideration

For and on Behalf of Board of Directors of  
Mesco Pharmaceuticals Limited

*Dhruv Singh*

Date : 03.09.2020  
Place : New Delhi

Dhruv Singh  
Director & CEO